The global acute kidney injury treatment market size was valued at USD 2.23 billion in 2025 and is projected to grow from USD 2.39 billion in 2026 to USD 4.18 billion by 2034, registering a CAGR of 7.24% during the forecast period (2026-2034). North America dominated the acute kidney injury treatment market with a share of 40.03% in 2025.
Acute kidney injury (AKI) treatment includes medical interventions designed to address a sudden decline in kidney function, manage complications, and support renal recovery. They are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The acute kidney injury treatment market demand is driven by the rising burden of kidney injury associated with critical illness, surgery, infections, and medication-related complications. Healthcare providers are using supportive drug therapies, electrolyte management, hemodialysis, and continuous renal replacement therapy (CRRT), contributing to acute kidney injury treatment market growth.
Download a Free Sample To learn more about this report,
Shift toward Early Detection and Targeted Treatment of Acute Kidney Injury
The acute kidney injury treatment market analysis shows a shift toward early detection and targeted treatment to prevent kidney damage from progressing to severe complications. Healthcare providers are increasingly using risk assessment tools, kidney function tests, and patient-specific clinical information to guide treatment decisions.
Adoption of Biomarker-Based Kidney Injury Assessment
Biomarker-based kidney injury assessment is shaping the acute kidney injury treatment market by helping identify kidney damage before conventional indicators show significant changes. Biomarkers such as NGAL and TIMP 2 multiplied by IGFBP7 can help assess kidney injury risk and support clinical decision-making. This development is improving early risk identification and supporting more timely treatment and monitoring.
Supply chain disruptions are expected to have a high impact on the acute kidney injury treatment market share due to dependence on essential medicines and dialysis consumables. The market is expected to follow a stair-step recovery, as delays in pharmaceutical production can affect treatment availability. The market is expected to grow at a CAGR of 7.24%, but supply chain constraints could lower this by 1.0 percentage point, resulting in a growth of around 6.24%. As supply conditions normalize, the acute kidney injury treatment market growth is expected to gradually return to 7.24%.
The acute kidney injury treatment market forecasts strategic investment activity driven by clinical research into kidney recovery. In September 2026, Vincere Biosciences received a USD 2.7 million Phase II SBIR grant from the U.S. National Institutes of Health to advance its USP30 inhibitor through preclinical safety studies toward clinical development for acute kidney injury.
Expansion of Continuous Renal Replacement Therapy Programs and Demand for Better Management of Drug-Induced Kidney Injury Drive Market
Expansion of continuous renal replacement therapy (CRRT) programs is increasing access to advanced treatment for patients with severe acute kidney injury, particularly those in intensive care units. CRRT gradually removes waste products and excess fluid while helping maintain electrolyte balance in critically ill patients who may not tolerate conventional dialysis. Investment in critical care facilities, specialized equipment, and trained healthcare personnel is supporting the use of CRRT.
Need for better management of drug-induced kidney injury is increasing, as certain medications can impair kidney function, particularly in vulnerable patients and those receiving multiple treatments. Healthcare providers require effective approaches to identify kidney damage, adjust medication use, and provide timely supportive care. Improved monitoring and appropriate treatment can help limit further injury and support kidney function recovery.
High Burden of Comorbidities and Complications Associated with Dialysis Restraints Market Expansion
High burden of comorbidities among patients can complicate acute kidney injury treatment. Conditions such as diabetes, cardiovascular disease, and chronic kidney disease can affect kidney recovery and increase the risk of additional complications. These underlying health conditions may require complex treatment plans and closer medical supervision, increasing healthcare costs and making successful recovery more difficult.
Risk of complications associated with dialysis can create challenges in treating severe acute kidney injury. Patients undergoing dialysis may experience low blood pressure, infections, bleeding, or problems related to vascular access. These complications can require additional medical intervention and extend hospital stays, increasing the overall treatment burden.
Acute Kidney Injury Treatment in Post-Surgical Care and Follow-Up Care Services Open New Revenue Sources for Market Players
Pharmaceutical companies and medical device manufacturers can target hospitals and surgical centers managing patients at risk of kidney injury following major operations. Revenue can be generated through hospital supply contracts for intravenous fluids, prescribed medications, renal support equipment, and procedure-specific consumables, contributing to acute kidney injury treatment market growth.
Hospitals, nephrology clinics, and outpatient care providers can develop follow-up services for patients recovering from acute kidney injury. These services can include kidney function assessments, medication reviews, laboratory testing, and monitoring for persistent renal impairment.
Pre-renal acute kidney injury led the disease type segment with a share of 46.2% in 2025 due to kidney dysfunction associated with reduced blood flow due to dehydration, and cardiovascular complications. Early treatment focuses on restoring circulation, correcting fluid imbalances, and addressing the underlying cause to prevent further kidney damage.
Intrinsic renal acute kidney injury is projected to register a CAGR of 7.76% during the forecast period, driven by the need for targeted treatment approaches addressing direct damage to kidney tissues caused by conditions such as acute tubular injury and drug-induced toxicity.
Request Customizationto receive a tailored report.
Renal replacement therapy (RRT) led the treatment type segment in 2025, accounting for a share for 42.6% of the market, reflecting its critical role in managing severe kidney dysfunction by supporting fluid balance and removing waste products when kidney function is significantly impaired.
The immunosuppressive agents segment is anticipated to record a CAGR of 8.06% during the forecast period, driven by the need to manage selected immune-mediated causes of kidney injury. Advances in identifying underlying immune mechanisms can help clinicians select appropriate therapies for eligible patients.
Speak to an Analystto discuss market opportunities.
The North America acute kidney injury treatment market accounted for a dominant share of 40.03% in 2025.
U.S. market benefits from the availability of acute kidney injury management and dialysis services in specialized hospital intensive care units. At the University of Chicago Medical Center, critical care nephrology services focus on managing acute kidney injury in critically ill patients, including those requiring acute dialysis and continuous renal replacement therapy (CRRT). These services address the need for gradual fluid removal, electrolyte management, and kidney support among patients.
In Canada, Kingston Health Sciences Centre upgraded its continuous renal replacement therapy equipment to strengthen kidney support for critically ill patients in its intensive care unit. The facility serves patients from southeastern Ontario who require continuous dialysis because their condition may not allow them to tolerate standard hemodialysis.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific acute kidney injury treatment market is projected to grow at a CAGR of 8.96%, making it the fastest-growing region.
Chinese Society of Critical Care Medicine published updated clinical practice guidelines for renal replacement therapy in critically ill patients with acute kidney injury, providing 34 recommendations covering treatment initiation, therapy selection, and vascular access. China’s National Health Commission issued a 2026 guideline for establishing and operating primary-level hemodialysis units, supporting improvements in dialysis infrastructure and service delivery.
India’s renal treatment infrastructure is expanding through the Pradhan Mantri National Dialysis Programme (PMNDP), launched under the National Health Mission to improve access to affordable dialysis services. The program supports the availability of hemodialysis services across the country.
Japanese Clinical Practice Guideline for Acute Kidney Injury focuses on national nephrology, intensive care, dialysis, blood purification, and pediatric nephrology societies. These guidance addresses treatment decisions such as managing fluid overload, correcting electrolyte and acid-base disturbances, and selecting continuous or intermittent renal replacement therapy according to the patient’s condition.
The Europe acute kidney injury treatment market is estimated to grow at a CAGR of 6.92%.
UK's National Institute for Health and Care Excellence (NICE) provides clinical guidance on identifying acute kidney injury, monitoring serum creatinine, and assessing urine output to support timely intervention. These recommendations create opportunities for treatment providers offering fluid management solutions to help hospitals manage kidney complications and improve patient outcomes.
Germany benefits from efforts to strengthen intensive care practices and improve the management of critically ill patients with kidney dysfunction. German university hospitals, including Charité–Universitätsmedizin Berlin, provide specialized nephrology and intensive care services for patients requiring kidney support. These clinical capabilities create opportunities for providers of electrolyte monitoring systems and renal replacement therapy solutions.
The Latin America acute kidney injury treatment market is likely to grow at a CAGR of 7.41%. The Brazilian Society of Nephrology has developed hospital nephrology care guidelines covering non-dialysis kidney support, hospital dialysis procedures, and follow-up care after acute kidney injury.
In Mexico, the state of Zacatecas expanded access to renal treatment by launching a free hemodialysis service in Pinos. The expansion specifically includes treatment for patients with acute or chronic kidney failure, improving access for people in underserved communities.
Middle East & Africa's acute kidney injury treatment market is projected to grow at a CAGR of 7.68%. In the UAE, the Emirates Health Services network provides renal care and dialysis services through its public healthcare facilities. Access to these services is important for patients with severe acute kidney injury who develop fluid overload, electrolyte disturbances, or a need for temporary dialysis.
In South Africa, King Edward VIII Hospital in Durban evaluated serum procalcitonin levels as a predictor of acute kidney injury among critically ill patients.
The acute kidney injury treatment market competitive landscape is highly fragmented, with specialty drug developers, renal care providers, and hospital medicine suppliers. Key players such as Pfizer, Novartis, Sanofi, Teva Pharmaceutical, and Fresenius Kabi are estimated to account for 25–30% of the global acute kidney injury treatment market share.
Established players compete mainly through supportive drug therapies and renal replacement therapy support. Emerging and regional players in the acute kidney injury treatment market ecosystem focus on improved treatment protocols and solutions for managing drug-induced kidney injury.
March 2026: SeaStar Medical completed enrollment of 50 patients in its FDA-required SAVE Registry, advancing post-approval safety monitoring of QUELIMMUNE for children with acute kidney injury associated with sepsis who require renal replacement therapy.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Congenital Hyperinsulinism Treatment Market Size, Opportunities, 2034
Clinical Trial Packaging Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Cryptococcosis Market Size, Forecast, Demand, Opportunities, 2034
Apixaban Market Size, Forecast, Demand, Opportunities, 2034
Asbestosis Treatment Market Size, Forecast, Demand, 2034
We are featured on:
sales@straitsresearch.com